Precigen Inc. Common Stock (PGEN)

About PGEN

Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, a…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

160

Website

precigen.com/

Fundamentals

1-day range

$6.92$7.19

Market cap

$2.36B

P/E (trailing)

—

P/E (forward)

-31.59

EPS (trailing)

$-0.52

Dividend yield

—

Beta

0.98

Avg. volume

5.46M

Forecasts

2 analyst ratings

Precigen Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• PGEN

  Precigen Inc. Common Stock

  $6.94

  ▼ 3.55%
  Market cap $2.36BP/E —
  $2.99$7.72
• NKTR

  Nektar Therapeutics Common Stock

  $72.57

  ▼ 2.66%
  Market cap $2.38BP/E —
  $27.87$109
• VERA

  Vera Therapeutics Inc. Class A Common Stock

  $34.19

  ▼ 1.18%
  Market cap $2.31BP/E —
  $21.2$56.05
• RARE

  Ultragenyx Pharmaceutical Inc. Common Stock

  $25.62

  ▼ 2.46%
  Market cap $2.46BP/E —
  $18.29$39.89
• KLRA

  Kailera Therapeutics Inc. Common Stock

  $16.26

  ▼ 12.25%
  Market cap $2.24BP/E —
  $16.19$28.23
• TRVI

  Trevi Therapeutics Inc. Common Stock

  $16.78

  ▼ 6.60%
  Market cap $2.54BP/E —
  $6.93$20.22
• NUVB

  Nuvation Bio Inc. Class A Common Stock

  $6.67

  ▼ 4.65%
  Market cap $2.14BP/E —
  $2.87$9.75

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• HC Wainwright & Co. Maintains Buy on Precigen, Raises Price Target to $18
  benzinga · 8/5/2026

Institutional Ownership

March 31, 2026

Total shares held

131.60M

Total value held

$504.18M

Institutional holders

197